cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLCcardiovascular-1419Research ArticleМНЕНИЕ ПО ПРОБЛЕМЕOPINION ON A PROBLEMНовые возможности в лечении пациента высокого сердечно-сосудистого риска. Розувастатин и перспективы его применения в клинической практикеNew perspectives in treating high-risk cardiac patients. Rosuvastain and it’s perspectives for clinical practice useБубноваМ. Г.BubnovaM. G.oganov@gnicpm.ruГосударственный научно-исследовательский центр профилактической медицины Росмедтехнологии; Московская медицинская академия им. И.М.Сеченова, МоскваState Research Center for Preventive Medicine, Federal Agency on High Medical Technologies; I.M. Sechenov Moscow Medical Academy, Moscow200720122007667582Copyright © Бубнова М.Г., 20072007Бубнова М.Г.Bubnova M.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/1419

В настоящем обзоре изложены современные принципы гиполипидемической терапии, приводящие к снижению риска сердечно-сосудистых осложнений. Обозначены основные группы пациентов, требующие раннего и активного назначения гиполипидемической терапии, в первую очередь, статинов. Изложена новая тактика назначения статинов, основанная на результатах последних завершенных крупных исследований. В обзоре приведены данные клинических исследований, изучающих гиполипидемические и антиатеросклеротические эффекты розувастатина – статина новой генерации; обозначены его фармакологические особенности и определены перспективы применения в клинической практике.

The review summarizes modern principles of lipid-lowering therapy aimed at cardiovascular event risk reduction. The author describes main patient groups in need for early, aggressive lipid-lowering therapy – predominantly, statin therapy. New statin treatment tactics is presented, based on the latest results of recent large-scale clinical trials. The article also contains the results of clinical trials on a new generation statin, rosuvastatin, its lipid-lowering and anti-atherosclerotic effects, its pharmacological features and clinical use perspectives.

гиполипидемическая терапиястатинырозувастатинвысокий рискхолестерин липопротеидов низкой плотностицелевые уровниlipid-lowering therapystatinsrosuvastatinhigh risklow-density lipoprotein cholesteroltarget levelsReferencesШальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в Российской популяции. Кардиоваск тер профил 2005; 4(1): 4-9.Шальнова С.А., Деев А.Д., Оганов Р.Г. Факторы, влияющие на смертность от сердечно-сосудистых заболеваний в Российской популяции. Кардиоваск тер профил 2005; 4(1): 4-9.Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.Grundy SM, Cleeman JI, Merz CN, et al. National Heart, Lung, and Blood Institute; American College of Cardiology Foundation; American Heart Association. Implications of recent clinical trial for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safely of cholesterol-lowering treatments: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-78.Baigent C, Keech A, Kearney PM, et al. Cholesterol Treatment Trialists (CTT) Collaborators. Efficacy and safely of cholesterol-lowering treatments: prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-78.Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at of vascular disease (PROSPER) randomized controlled trial. Lancet 2002; 360: 1623-30.Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at of vascular disease (PROSPER) randomized controlled trial. Lancet 2002; 360: 1623-30.LaRose JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 353: 1425-35.LaRose JC, Grundy SM, Waters DD, et al. Treating to New Targets (TNT) Investigators. Intensive lipid lowering atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 353: 1425-35.EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 2000; 74(Suppl): S23-8.Pearson TA. The undertreatment of LDL-cholesterol: addressing the challenge. Int J Cardiol 2000; 74(Suppl): S23-8.Ganse EV, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005; 21: 1389-99.Ganse EV, Laforest L, Alemao E, et al. Lipid-modifying therapy and attainment of cholesterol goals in Europe: the Return on Expenditure Achieved for Lipid Therapy (REALITY) study. Curr Med Res Opin 2005; 21: 1389-99.Оганов Р.Г., Лепахин И.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии напряжения в Российской Федерации (международное исследование АТР - Angina Treatment Pattern). Кардиология 2003; 5: 9-15.Оганов Р.Г., Лепахин И.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии напряжения в Российской Федерации (международное исследование АТР - Angina Treatment Pattern). Кардиология 2003; 5: 9-15.Шальнова С.А., Деев А.Д. Уроки ОСКАР – «Эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005-2006г.». Кардиоваск тер профил 2007; 6: 47-53.Шальнова С.А., Деев А.Д. Уроки ОСКАР – «Эпидемиология и особенности терапии пациентов высокого риска в реальной клинической практике 2005-2006г.». Кардиоваск тер профил 2007; 6: 47-53.McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of efficacy of rosuvastatin verus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-98.McKenney JM, Jones PH, Adamczyk MA, et al. Comparison of efficacy of rosuvastatin verus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin 2003; 19: 689-98.Olsson AG, McTaggart F, Roza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303-28.Olsson AG, McTaggart F, Roza A. Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor. Cardiovasc Drug Rev 2002; 20: 303-28.White CM. A reviews of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-70.White CM. A reviews of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42: 963-70.Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003; 91 (Suppl): 3C-10.Blasetto JW, Stein EA, Brown WV, et al. Efficacy of rosuvastatin compared with other statins at selected starting doses in hypercholesterolemic patients and in special population groups. Am J Cardiol 2003; 91 (Suppl): 3C-10.Stein E, Ssrutt KL, Miller E, et al. Comparison of rosuvastatin verus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003; 8: 383-90.Stein E, Ssrutt KL, Miller E, et al. Comparison of rosuvastatin verus atorvastatin in patients with heterozygous familial hypercholesterolemia. Am J Cardiol 2003; 8: 383-90.Schuster H. Rosuvastatin – a highly effect new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor: review of clinical trial at 10-40 mg disease in dyslipidemic patients. Cardiology 2003; 99: 126-39.Schuster H. Rosuvastatin – a highly effect new 3-hydroxy-3- methylglutaryl coenzyme A reductase inhibitor: review of clinical trial at 10-40 mg disease in dyslipidemic patients. Cardiology 2003; 99: 126-39.Hunninghake DB, Stein EA, Bays HE, et al. Rosuvastatin improves the atherogenic and artheroprotective lipid profile in patients with hypertriglyceridaemia. Coron Artery Dis 2004; 15: 115-23.Hunninghake DB, Stein EA, Bays HE, et al. Rosuvastatin improves the atherogenic and artheroprotective lipid profile in patients with hypertriglyceridaemia. Coron Artery Dis 2004; 15: 115-23.Ballantyne CM, Stein EA, Paoletii R, et al. Effocacy of rosuvas- tatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003; 91(Suppl): 25C-8.Ballantyne CM, Stein EA, Paoletii R, et al. Effocacy of rosuvas- tatin 10 mg in patients with the metabolic syndrome. Am J Cardiol 2003; 91(Suppl): 25C-8.Copin C, Davidson R, McTaggart F, et al. Rosuvastatin reduces MMP-9 and MMP-7 secretion by human monocyte-derived macrophages. Int J Clin Pract 2002; 124(Suppl): 7.Copin C, Davidson R, McTaggart F, et al. Rosuvastatin reduces MMP-9 and MMP-7 secretion by human monocyte-derived macrophages. Int J Clin Pract 2002; 124(Suppl): 7.Retteridge D, Gibson M. Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes; results of the ANDROMEDA study. Atherosclerosis 2004; 5(Suppl): 107 Abs M464.Retteridge D, Gibson M. Effect of rosuvastatin and atorvastatin on LDL-C and CRP levels in patients with type 2 diabetes; results of the ANDROMEDA study. Atherosclerosis 2004; 5(Suppl): 107 Abs M464.Napoli PD, Taccardi AA, Grilli A, et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia/reperfusion injury in rat hearts Cardiovasc Res 2005; 66: 462-71.Napoli PD, Taccardi AA, Grilli A, et al. Chronic treatment with rosuvastatin modulates nitric oxide synthase expression and reduces ischemia/reperfusion injury in rat hearts Cardiovasc Res 2005; 66: 462-71.Schuster H. The GALAXY Program: an update on studies intestigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5: 177-92.Schuster H. The GALAXY Program: an update on studies intestigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk. Expert Rev Cardiovasc Ther 2007; 5: 177-92.Nissen SE, Stephen JN, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295: 1556-65.Nissen SE, Stephen JN, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA 2006; 295: 1556-65.Nissen SE, Tuzcu EM, Brown BG, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 2004; 291: 1071-80.Nissen SE, Tuzcu EM, Brown BG, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial JAMA 2004; 291: 1071-80.Buchwald H, Matts JP, Fitch LL. The Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. “Changes in seduential coronary arteriograms and subsequent coronary events”. JAMA 1992; 268: 1429-33.Buchwald H, Matts JP, Fitch LL. The Program on the Surgical Control of the Hyperlipidemias (POSCH) Group. “Changes in seduential coronary arteriograms and subsequent coronary events”. JAMA 1992; 268: 1429-33.Crouse III JR, Raichlen JS, Evans GW, et al. Effects of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical аtherosclerosis. The METEOR trial. JAMA 2007; 297: 1344-53.Crouse III JR, Raichlen JS, Evans GW, et al. Effects of Rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical аtherosclerosis. The METEOR trial. JAMA 2007; 297: 1344-53.Cheng WM. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004; 26: 1368-87.Cheng WM. Rosuvastatin in the management of hyperlipidemia. Clin Ther 2004; 26: 1368-87.

The authors declare that there are no conflicts of interest present.